MedTrace Logo

Sarcopenia Predictors in Patients With COPD

NCT07509528 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2026-04-09

No results posted yet for this study

Summary

Chronic obstructive pulmonary disease (COPD) is a significant, preventable, and treatable public health problem and a growing cause of chronic morbidity and mortality worldwide. Frailty is a biological syndrome resulting from a progressive decrease in the reserve capacity of multiple physiological systems. COPD and frailty are closely associated with common risk factors such as aging, tobacco use, impaired neuroendocrine function, immune system dysfunction, and chronic inflammation.

Cardiopulmonary exercise testing (CPET) is a valuable tool for assessing exercise capacity, evaluating the severity of limitations, and identifying their causes. CPET provides an objective measurement of exercise capacity with direct applications in risk stratification. It also guides rehabilitation practices, including the planning and prescription of exercise training.

COPD is associated with a systemic inflammatory process that can lead to progressive loss of muscle mass and function and sarcopenia. The prevalence of COPD in sarcopenic patients varies between 4.4% and 86.55% due to the variability of various diagnostic tools, different reference values, and threshold values presented in the literature Further research is needed in the literature regarding the role of sarcopenia and factors that may affect sarcopenia, such as cardiorespiratory exercise capacity, in a specific lung disease like COPD.

The primary aim of this study was to examine the differences in respiratory function, respiratory muscle strength, cardiopulmonary exercise capacity, rectus femoris muscle thickness, activities of daily living, balance, and frailty parameters among patients with possible sarcopenic, sarcopenic, and severe sarcopenic COPD.

The secondary aim of this study was to identify the factors affecting sarcopenia in COPD patients.

Conditions

Sponsors & Collaborators

  • Bursa City Hospital

    collaborator OTHER_GOV

  • Hacettepe University

    lead OTHER

Principal Investigators

  • Sezen Kayalı, MsC · Bursa City Hospital

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-05-29
Completion
2025-05-29

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07509528 on ClinicalTrials.gov